XOLAIR 150  

SAN ANTONIO, Texas — Omalizumab (Xolair, Roche, Genentech, Novartis) appears to be safe and effective in the treatment of chronic idiopathic urticaria that is refractory to antihistamines, according to new phase 3 clinical trial results.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()